Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177292 | 0.95 | DRD2 (0.91) | DRD2DRD3 | |
| SCHEMBL1999795 | 0.90 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL1995575 | 0.90 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL1999175 | 0.90 | DRD2 (0.81) | DRD2DRD3 | |
| SCHEMBL2002877 | 0.87 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL2348732 | 0.86 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL2352216 | 0.86 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL2349033 | 0.85 | DRD2 (1.00) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2351644 | 0.85 | DRD2 (0.98) | DRD2DRD3 | |
| SCHEMBL2355000 | 0.84 | DRD2 (0.84) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763522-B1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8334289-B2 | Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-7960386-B2 | 1-(4-{4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-4-methylpyridin-2(1H)-one; treatment of schizophrenia and/or depression | ABBOTT GMBH & CO. KG (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | DRD3, DRD2, PTGDR | DRD2 2/4885DRD3 1/4885 |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | DRD3, DRD2, MTNR1A | DRD2 2/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.